Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.

Abstract

rhGM-CSF at 5 to 10 micrograms/kg reduces chemotherapy-associated neutropenia and should be the dose range used in future studies.

Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: A report from the Australia and New Zealand Children's Cancer Study Group

“…Recombinant CSFs, particularly granulocyte-macrophage colonystimulating factor (GM-CSF) [1][2][3] and granulocyte colony-stimulating factor (G-CSF) [4,5], have been developed for clinical use and have been studied in several clinical settings in an effort to enhance neutrophil numbers and function. Areas of study have included disease states such as congenital or acquired neutropaenias [6], and treatment-related neutropaenia following high-dose chemotherapy or bone marrow transplantation [3,5,[7][8][9].…”

Thrombocytopenia and hemostatic disorders in chronic graft versus host disease

“…13 In addition, it was observed that both granulocyte-macrophage-CSF and M-CSF in pharmacologic doses may reduce platelet counts in a dose-dependent manner or delay platelet recovery after chemotherapy. 54,[74][75][76] Additionally, though donor treatment with G-CSF may decrease the ability of donor T cells to induce aGVHD, it may also contribute to increase the severity of cGVHD. 77,78 The role of transforming growth factor-beta (TGF-b) in this process was assessed in a murine model of aGVHD and cGVHD.…”

Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer

“…The increase in cytotoxic dose-intensity in the G-CSF group was associated with a better 2 year survival rate (32 versus 15%) [55]. HAMM et al [41] also demonstrated a higher dose-intensity for GM-CSF treated patients with the CDE regimen [41]. Others phase II studies have suggested the possibility of increasing dosage of chemotherapy by 20-40% with CSF support [56][57][58], but survival data are not available.…”

“…A randomized study using molgramostim (Leucomax®) versus placebo after CDE chemotherapy in 148 patients with SCLC resulted in faster neutrophil recovery, less severe neutropenia, and reduced antibiotic use during the first cycle of chemotherapy, but with no significant effect on the incidence of febrile-neutropenia and chemotherapy dose-intensity [41].…”